SLC22A15 and acute lymphoblastic leukemia: This deconvolution of the methylation patterns, identifying only a comparatively small number of methylation changes that are truly disease specific, opens up new opportunities for utilising true disease associated methylation changes to identify novel cancer drivers and therapeutic targets, as illustrated here by the identification of SLC22A15 as a novel tumour suppressor candidate in ALL.